JP2019537449A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537449A5 JP2019537449A5 JP2019527171A JP2019527171A JP2019537449A5 JP 2019537449 A5 JP2019537449 A5 JP 2019537449A5 JP 2019527171 A JP2019527171 A JP 2019527171A JP 2019527171 A JP2019527171 A JP 2019527171A JP 2019537449 A5 JP2019537449 A5 JP 2019537449A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- abp
- cdr
- sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims 195
- 108091000831 antigen binding proteins Proteins 0.000 claims 195
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 76
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 67
- 239000000427 antigen Substances 0.000 claims 46
- 102000036639 antigens Human genes 0.000 claims 46
- 108091007433 antigens Proteins 0.000 claims 46
- 239000003814 drug Substances 0.000 claims 38
- 210000004027 cell Anatomy 0.000 claims 36
- 239000002773 nucleotide Substances 0.000 claims 34
- 125000003729 nucleotide group Chemical group 0.000 claims 34
- 239000002157 polynucleotide Substances 0.000 claims 32
- 102000040430 polynucleotide Human genes 0.000 claims 32
- 108091033319 polynucleotide Proteins 0.000 claims 32
- 239000012634 fragment Substances 0.000 claims 28
- 239000013604 expression vector Substances 0.000 claims 23
- 230000003308 immunostimulating effect Effects 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 229960001438 immunostimulant agent Drugs 0.000 claims 11
- 239000003022 immunostimulating agent Substances 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 10
- 210000003289 regulatory T cell Anatomy 0.000 claims 10
- 102000047758 human TNFRSF18 Human genes 0.000 claims 9
- 235000001014 amino acid Nutrition 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims 7
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims 6
- 101000912551 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Fimbrin Proteins 0.000 claims 6
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 5
- -1 EGFR inhibitors Substances 0.000 claims 5
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims 4
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims 4
- 210000002865 immune cell Anatomy 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 101000732629 Drosophila melanogaster Anillin Proteins 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 3
- 239000013059 antihormonal agent Substances 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229940121647 egfr inhibitor Drugs 0.000 claims 3
- 239000003966 growth inhibitor Substances 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- 230000001629 suppression Effects 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 102100039160 Amiloride-sensitive amine oxidase [copper-containing] Human genes 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 101710167313 Drebrin-like protein Proteins 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 2
- 101100029157 Homo sapiens PEF1 gene Proteins 0.000 claims 2
- 102100025390 Integrin beta-2 Human genes 0.000 claims 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- 102100035845 Peflin Human genes 0.000 claims 2
- 101100000443 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ACC1 gene Proteins 0.000 claims 2
- 101100489940 Schizosaccharomyces pombe (strain 972 / ATCC 24843) abp2 gene Proteins 0.000 claims 2
- 230000006052 T cell proliferation Effects 0.000 claims 2
- 101100489942 Zea mays ABP4 gene Proteins 0.000 claims 2
- 101100489943 Zea mays ABP5 gene Proteins 0.000 claims 2
- 101100108219 Zea mays ADF2 gene Proteins 0.000 claims 2
- 101100108223 Zea mays ADF3 gene Proteins 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 108091008042 inhibitory receptors Proteins 0.000 claims 2
- 244000309459 oncolytic virus Species 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 230000009466 transformation Effects 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 241000711404 Avian avulavirus 1 Species 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100024263 CD160 antigen Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- 101710185679 CD276 antigen Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 101150046249 Havcr2 gene Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 1
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 102000002698 KIR Receptors Human genes 0.000 claims 1
- 108010043610 KIR Receptors Proteins 0.000 claims 1
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 101100425749 Mus musculus Tnfrsf18 gene Proteins 0.000 claims 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 1
- 102100028749 Neuritin Human genes 0.000 claims 1
- 101710189685 Neuritin Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 101100489939 Prunus persica ABP20 gene Proteins 0.000 claims 1
- 102100029198 SLAM family member 7 Human genes 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000008484 agonism Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 230000030741 antigen processing and presentation Effects 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000005931 immune cell recruitment Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 230000001839 systemic circulation Effects 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662497428P | 2016-11-19 | 2016-11-19 | |
| US62/497,428 | 2016-11-19 | ||
| US201762448644P | 2017-01-20 | 2017-01-20 | |
| US62/448,644 | 2017-01-20 | ||
| PCT/US2017/062443 WO2018094300A1 (en) | 2016-11-19 | 2017-11-19 | Anti-gitr antigen-binding proteins and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019537449A JP2019537449A (ja) | 2019-12-26 |
| JP2019537449A5 true JP2019537449A5 (cg-RX-API-DMAC7.html) | 2021-01-07 |
| JP7572147B2 JP7572147B2 (ja) | 2024-10-23 |
Family
ID=62146165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019527171A Active JP7572147B2 (ja) | 2016-11-19 | 2017-11-19 | 抗ｇｉｔｒ抗原結合タンパク質およびその使用方法 |
Country Status (17)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102239781B1 (ko) * | 2019-04-08 | 2021-04-13 | 주식회사 녹십자 | Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 |
| US10994021B1 (en) * | 2020-04-11 | 2021-05-04 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. | Tetravalent antibody-drug conjugates and use thereof |
| EP4161655A2 (en) | 2020-06-08 | 2023-04-12 | University of Washington | Antibody-bound nanoparticles |
| WO2022240161A1 (ko) * | 2021-05-10 | 2022-11-17 | 메디맵바이오 주식회사 | 항-gitr 항체 및 이의 용도 |
| WO2023094507A1 (en) * | 2021-11-24 | 2023-06-01 | Formycon Ag | Improved ace2 fusion proteins |
| CA3243774A1 (en) | 2022-03-15 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Anti-Glucocorticoid-Induced TNFR-Related Protein (GITR) Antibodies and Their Uses |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL97459A0 (en) | 1990-03-09 | 1992-06-21 | Hybritech Inc | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
| JP3571337B2 (ja) | 1992-02-11 | 2004-09-29 | セル ジェネシス，インコーポレーテッド | 遺伝子標的現象による同型遺伝子接合 |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| US5945403A (en) | 1997-05-30 | 1999-08-31 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| PT994903E (pt) | 1997-06-24 | 2005-10-31 | Genentech Inc | Metodos e composicoes para glicoproteinas galactosiladas |
| US6503184B1 (en) | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| EP1028751B1 (en) | 1997-10-31 | 2008-12-31 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US7550143B2 (en) | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| MXPA02010011A (es) | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| EP1189379A1 (en) | 2000-09-14 | 2002-03-20 | Alcatel | Method and system for enhancing channel capacity in a point to multipoint radio communications system |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| ES2360479T3 (es) | 2000-12-18 | 2011-06-06 | Dyax Corp. | Bibliotecas focalizadas de paquetes genéticos. |
| US20030133936A1 (en) | 2001-07-12 | 2003-07-17 | Byrne Michael Chapman | CD25markers and uses thereof |
| RU2321630C2 (ru) | 2001-08-03 | 2008-04-10 | Гликарт Биотекнолоджи АГ | Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US6715202B2 (en) | 2001-11-02 | 2004-04-06 | American Standard International Inc. | Tube bender for forming serpentine heat exchangers from spine fin tubing |
| US6579430B2 (en) | 2001-11-02 | 2003-06-17 | Innovative Technology Licensing, Llc | Semiconductor wafer plating cathode assembly |
| US20030215914A1 (en) | 2001-12-10 | 2003-11-20 | Erwin Houtzager | Structure for presenting desired peptide sequences |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| US7749753B2 (en) | 2002-04-09 | 2010-07-06 | Kyowa Hakko Kirin Co., Ltd | Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
| JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
| PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004056312A2 (en) | 2002-12-16 | 2004-07-08 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| CN1753692A (zh) | 2002-12-20 | 2006-03-29 | 比奥根艾迪克Ma公司 | 淋巴毒素β受体药剂与化疗剂的联合用药 |
| JP4638876B2 (ja) | 2003-05-23 | 2011-02-23 | ワイス | Ｇｉｔｒリガンド及びｇｉｔｒリガンド関連分子及び抗体及びその使用 |
| WO2005007190A1 (en) | 2003-07-11 | 2005-01-27 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
| WO2005007150A2 (en) | 2003-07-17 | 2005-01-27 | Bar-Ilan University | Method for inhibiting protein synthesis in sperm |
| US6864697B1 (en) | 2003-08-06 | 2005-03-08 | Taiwan Semiconductor Manufacturing Co. Ltd | Flip-over alignment station for probe needle adjustment |
| US20050035586A1 (en) | 2003-08-12 | 2005-02-17 | Martin Samuel V. | Magnetically pulse welded underbody |
| JP2005081663A (ja) | 2003-09-08 | 2005-03-31 | Nissan Motor Co Ltd | 樹脂製チューブ及び燃料系配管用チューブ |
| RS55723B1 (sr) | 2003-11-05 | 2017-07-31 | Roche Glycart Ag | Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| JP4633788B2 (ja) | 2004-04-13 | 2011-02-16 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ｐ−セレクチン抗体 |
| EP1765402A2 (en) | 2004-06-04 | 2007-03-28 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| AU2006232920B2 (en) | 2005-04-06 | 2011-09-29 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2007060918A1 (ja) | 2005-11-24 | 2007-05-31 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なメモリーｃｔｌ誘導増強剤 |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| AU2008275589B2 (en) | 2007-07-12 | 2013-11-21 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| CA2697193C (en) | 2007-09-14 | 2017-06-06 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| IN2012DN01920A (cg-RX-API-DMAC7.html) | 2009-09-03 | 2015-07-24 | Schering Corp | |
| CN102666582B (zh) | 2009-12-22 | 2016-03-30 | 弗·哈夫曼-拉罗切有限公司 | 序列依赖性聚集 |
| MX360336B (es) | 2010-07-16 | 2018-10-30 | Adimab Llc Star | Colecciones de anticuerpos. |
| CA2844538C (en) * | 2011-08-23 | 2020-09-22 | Roche Glycart Ag | Bispecific antigen binding molecules |
| MX349096B (es) | 2011-11-28 | 2017-07-11 | Merck Patent Gmbh | Anticuerpos anti-pd-l1 y sus usos. |
| EP3246339B1 (en) | 2012-03-28 | 2019-10-09 | Sanofi | Antibodies to bradykinin b1 receptor ligands |
| CN103217489B (zh) * | 2013-01-15 | 2016-03-09 | 珠海市丽珠单抗生物技术有限公司 | 一种测定蛋白纯化工艺过程中样品的糖基化和末端修饰情况的方法 |
| UY35517A (es) * | 2013-04-04 | 2014-10-31 | Mabxience S A | Un procedimiento para aumentar la formación de ácido piroglutamico de una proteína |
| HK1225742A1 (zh) * | 2013-08-22 | 2017-09-15 | Acceleron Pharma, Inc. | TGF-β受体II型变体及其用途 |
| JP6553042B2 (ja) * | 2013-09-05 | 2019-07-31 | ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ | 変更されたグリコシル化パターンを有するＦｃ含有分子を産生する細胞並びにその方法及び使用 |
| KR102056963B1 (ko) | 2013-12-30 | 2019-12-17 | 에피맙 바이오테라퓨틱스 인코포레이티드 | Fabs-인-탠덤 면역글로불린 및 이의 용도 |
| CA2949998A1 (en) | 2014-05-28 | 2015-12-03 | Agenus Inc. | Anti-gitr antibodies and methods of use thereof |
| CN110658340B (zh) * | 2015-01-08 | 2023-10-31 | 苏州康宁杰瑞生物科技有限公司 | 具有共同轻链的双特异性抗体或抗体混合物 |
| CN108883173B (zh) * | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | 抗体和其使用方法 |
-
2017
- 2017-06-16 JO JOP/2019/0100A patent/JOP20190100A1/ar unknown
- 2017-11-19 CN CN201780071351.3A patent/CN110248960A/zh active Pending
- 2017-11-19 KR KR1020197017116A patent/KR102574071B1/ko active Active
- 2017-11-19 MX MX2019005821A patent/MX2019005821A/es unknown
- 2017-11-19 BR BR112019010128A patent/BR112019010128A2/pt unknown
- 2017-11-19 WO PCT/US2017/062443 patent/WO2018094300A1/en not_active Ceased
- 2017-11-19 JP JP2019527171A patent/JP7572147B2/ja active Active
- 2017-11-19 AU AU2017362721A patent/AU2017362721A1/en not_active Abandoned
- 2017-11-19 EP EP17817953.7A patent/EP3541845A1/en active Pending
- 2017-11-19 UA UAA201906793A patent/UA126389C2/uk unknown
- 2017-11-19 MA MA046844A patent/MA46844A/fr unknown
- 2017-11-20 TW TW106140182A patent/TWI783953B/zh not_active IP Right Cessation
-
2018
- 2018-02-20 US US15/900,168 patent/US10988545B2/en active Active
-
2019
- 2019-05-10 ZA ZA2019/02939A patent/ZA201902939B/en unknown
- 2019-05-17 PH PH12019501108A patent/PH12019501108A1/en unknown
- 2019-05-19 IL IL266720A patent/IL266720A/en unknown
- 2019-06-19 CO CONC2019/0006424A patent/CO2019006424A2/es unknown
-
2021
- 2021-03-10 US US17/197,547 patent/US20210269542A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI788327B (zh) | 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途 | |
| JP2020511947A5 (cg-RX-API-DMAC7.html) | ||
| TWI773646B (zh) | 結合lag-3的分子和其使用方法 | |
| CN109641049B (zh) | Cd3结合抗体 | |
| JP2018533371A5 (cg-RX-API-DMAC7.html) | ||
| TWI758267B (zh) | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 | |
| JP2019537449A5 (cg-RX-API-DMAC7.html) | ||
| JP2020530289A5 (cg-RX-API-DMAC7.html) | ||
| JP2019517539A (ja) | 併用療法 | |
| JP2020536543A5 (cg-RX-API-DMAC7.html) | ||
| KR20190089090A (ko) | Pd-l1 항체와 이를 이용한 치료 및 진단 | |
| JP2024530451A (ja) | 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体及び応用 | |
| TW202241956A (zh) | 新穎抗cd24抗體 | |
| CN114901306A (zh) | 用于治疗癌症的疗法 | |
| JP2023518400A (ja) | 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法 | |
| JP2024138555A (ja) | 抗体製剤 | |
| US20230322953A1 (en) | Binding protein having h2l2 and hcab structures | |
| CN111886023A (zh) | 针对tim-3的抗体及其用途 | |
| JP2024054284A (ja) | ガンの処置のための結合分子 | |
| JP2025510232A (ja) | Ｉｌｔ３及びｃｄ３結合剤及びその使用方法 | |
| JP7486616B2 (ja) | Ｂｔｌａ抗体 | |
| TW202229348A (zh) | 使用sea-cd40治療葡萄膜黑色素瘤 | |
| US20250339519A1 (en) | Combination of cytokine fusion proteins with cd8 antigen binding molecules | |
| WO2025041097A1 (en) | Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof | |
| KR20220144821A (ko) | Cd137 결합 분자 및 그것의 용도 |